Therapy Areas: Central Nervous System
Saniona's co-founder and CFO to leave
19 February 2020 -

Saniona AB (STO:SANION), a clinical stage biotechnology company focused on rare diseases of the Central Nervous System, announced on Tuesday that Thomas Feldthus, co-founder and CFO, will be leaving the company.

According to Saniona, as a part of its strategic transformation it has initiated the search for a new CFO, who will be based in the US along with CEO Rami Levin. Feldthus, who is one of the co-founders of Saniona, will continue as CFO for an interim period to ensure a smooth transition and transfer of responsibilities to the new CFO.

Rami Levin, CEO of Saniona, stated that the company is rapidly advancing Tesomet towards pivotal clinical trials in the rare eating disorders Prader-Willi Syndrome and Hypothalamic Obesity. The expansion of its US organisation is a vital step towards its longer-term aim of becoming a global, commercial-stage company.